1VERDECHIAP, PORCELLATI C, REBOLDI G, et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension[J].Circulation,2001,104(17),2039-2044.
2DAHOF B, PENNERT K, HANSSON L. Reversal of left ventricular hypertrophy in hypertensive patients. A data analysis of 109 treatment studies[J]. Am J Hypertens,1992,5(2):95.
3URATA H, KINOSHITA A, MISONO K S, et al.Identification of a highly specific chymase as the major angiotension Ⅱ-forming enzyme in the human heart[J]. J Biol Chem,1990,265(36):22348-22357.
4HUSAIN A. The chymase-angiotension system in humans[J]. J Hypertens. 1993,11 (11 ):1155-1159.
5UR-ATA H, HOFFMANN S, GANTEN D. Tissue angiotension Ⅱ system in the human heart[J]. Eur Heart J, 1994,15 (Suppl D) : 68-78.
6NEUTEL J M, FRISHMAN W H, OPARIL S, et al.Comparison of telmisartan with lisinopril in patients with mildto-moderate hypertension[J]. Am J Ther, 1999,6(3) : 161-166.
7BOHM M,LEE M,KREUTZ R, et al, Angiotensin Ⅱ receptor blockade in TGR (mREN2) 27 : effects of rennin-angiotensinsystem gene expression and cardiac functions[J]. J Hypertens,1995,8(13) :891-899.
8LINZ W, SCHAPER J, WIEMER G, et al. Ramipril prevents left ventricular hepertrophy with myocardial fibrosis without blood pressure reductions A one year study in rats[J]. Br J Pharmacol, 1992,107(4) : 970-975.
